Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
UK medtech company Creavo Medical Technologies is trying to bring its magnetocardiography (MCG) technology to emergency departments worldwide to help physicians accurately rule out heart disease. Distinguishing between ischemic heart disease and non-cardiac chest pain remains a challenge in emergency departments. Currently, all patients presenting with chest pain are assessed with electrocardiography and blood tests to rule out heart disease, but almost three-quarters of patients with chest pain do not have a cardiac-related condition.
Aria CV hopes to address pulmonary hypertension, a potential devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization. See what Aria CEO John Scandurra said about it here.
St. Paul-based Aria CV is developing a "passive" pulmonary artery balloon system to treat pulmonary hypertension and impede the development of heart failure. Following a successful first-in-human study, the company is currently developing a feasibility study it expects will lead to a US pivotal trial in several years.
GNS Healthcare wants to be on the forefront of the digital revolution in health care by offering its artificial intelligence powers to pharmaceutical and health-insurer customers to help them find the drivers of health outcomes and save costs along the way. It has also teamed up with research and patient foundations to expedite the R&D process, predict best treatment options for patients and create efficiencies for clinical trials.
In an effort to make cardiac imaging more accessible and to lead to more appropriate diagnosis of cardiac disease, Bay Labs Inc. is developing software algorithms designed to allow echocardiography to be performed by non-specialists in echo, including medical providers such as nurses and physician assistants. The backbone of the technology is artificial intelligence (AI), specifically deep-learning algorithms.
In this edition of the Device Week podcast, Medtech Insight’s Reed Miller talks about the latest good news for LivaNova and Catherine Longworth provides an update on Creavo Medical, a UK-based company using an old technology for a new kind of cardiac test that could save hospitals money.
Swiss-based Vivior AG has developed a wearable Visual Behavior Monitor (VBM) designed to help surgical ophthalmologists determine the best treatment options for patients. The company's initial target is the $2.15bn global refractive and cataract surgery market.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.